Form 4: Director Steven Salamon Receives Delcath Systems Options

Director Steven A.J. Salamon was granted 22,500 stock options in Delcath Systems, Inc. as part of the company's equity incentive plan.

Summary

• Director Steven A.J. Salamon received a grant of 22,500 stock options for Delcath Systems, Inc. (DCTH) common stock.
• The options have an exercise price of $11.61 per share.
• The grant was issued on May 13, 2026, under the company's 2020 Omnibus Equity Incentive Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that carries no significant market signal.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The issuance of stock options results in potential future dilution for existing shareholders.

Risks

• The value of the options is dependent on the future market performance of Delcath Systems' common stock exceeding the $11.61 strike price.

Future Outlook

The options vest at a rate of 1/12th per month starting May 13, 2026, and expire 10 years from the grant date or two years after the director ceases service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice in the biotechnology sector to ensure board members are incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The use of a 10-year expiration and monthly vesting schedule is consistent with standard equity incentive plans for small-cap biotech companies.

Corporate Governance

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options to commence monthly starting June 2026.

Key Dates

Keywords

Delcath Systems, DCTH, Form 4, Insider Trading, Stock Options, Director Compensation